https://jpmorgan.metameetings.net/events/healthcare22/sessions/40550-sarepta-therapeutics-inc/webcast?gpu_only=true&kiosk=true
JP Morgan Downgrades Bright Health Gr to Neutral, Announces $2 Price Target
JP Morgan analyst Lisa Gill downgrades Bright Health Gr (NYSE:BHG) from Overweight to Neutral and announces $2 price target.